Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, April 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Cancer Drug

A class in a securities fraud dispute plausibly pleaded that some of cancer drug company NewLink’s statements about scientific literature and the design of their clinical trial may have amounted to material misrepresentations, the Second Circuit ruled.

MANHATTAN — A class in a securities fraud dispute plausibly pleaded that some of cancer drug company NewLink’s statements about scientific literature and the design of their clinical trial may have amounted to material misrepresentations, the Second Circuit ruled.

Categories / Appeals, Business, Health, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...